Navigation Links
Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
Date:9/16/2013

ATLANTA, Sept. 16, 2013 /PRNewswire/ -- Atlanta-based pharmaceutical discovery and development company, Celtaxsys, Inc., announced today the achievement of a significant clinical milestone for its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease. Celtaxsys has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd. In this First-in-Human trial, CTX-4430 was administered orally to Healthy Volunteers in escalating doses (up to 200 mg/day for 2 weeks) and was well-tolerated at all doses. Results of the trial will be presented at the 27th Annual North American Cystic Fibrosis Conference in October.

"This was a robust First-in-Human clinical trial assessing safety in 96 subjects. We're very pleased with the safety outcomes of CTX-4430 in this Healthy Volunteer study," said Dr. Ed Philpot, Celtaxsys CMO.  "These results support the continued clinical development of CTX-4430 as a once-daily oral treatment for pulmonary inflammation in CF."

CTX-4430 also exhibited excellent pharmacokinetic and pharmacodynamic properties in this study. "The 100 mg dose achieved maximal effect on its intended target, Leukotriene A4 Hydrolase, for the entire 24 hour period between doses," said Dr. Eric Springman, Celtaxsys CSO. "Having a biomarker to directly probe mechanism of action provides us with a much better understanding of the relationship between dose and effect and will be a tremendous help in the further clinical development of CTX-4430."

Said Mr. Ralph Grosswald, VP of Operations at Celtaxsys, "We had a great experience conducting our initial Phase 1 study of CTX-4430 in Australia. The entire process from start to fini
'/>"/>

SOURCE Celtaxsys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Celtaxsys Restructures, Enhances Operational Focus
2. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
3. Plastic Surgeon Dr. Marc J. Salzman Announces Use of Astanza Trinity Laser Tattoo Removal System, Runs Limited-Time Promotion
4. Sam Solakyan announces Paramount Management Services is now a full-scale MSO
5. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
6. Cell Therapeutics Announces Sale of Convertible Preferred Stock
7. Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
8. Goodwin Biotechnology Announces the Appointment of SooYoung S. Lee, PhD as Chief Operating Officer
9. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
10. Egalet Announces Financing to Fund Abuse-Deterrent Medications
11. PRA Holdings Announces Proposed Private Offering of $375 Million Senior Notes Due 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Bayer HealthCare LLC announced today that it has ... and Farnam Companies Inc. over Farnam,s advertising for its ... of the settlement, Farnam has agreed to withdraw the ... campaign included claims that Bio Spot® was "as effective ...
... CLARA, Calif., June 17, 2011 NewCardio, Inc., (OTC ... that Vincent Renz, Chief Executive Officer, is scheduled to ... Conference is on June 22 and 23, 2011, at ... 3:30 p.m. ET on Wednesday, June 22. ...
Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 3
(Date:1/23/2015)... AZ (PRWEB) January 23, 2015 Hastings and ... injury matters, reports a record number of legal representation client ... speaking, there has been a steady rise in the number ... work and at home throughout the Valley. With that said, ... accident be reviewed by an experienced law firm. Hastings and ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ST. LOUIS, June 5 Celebrities, from high-profile,athletes to ... products,including expensive energy drinks and even candy bars, are ... it is the nutrient fad of the,moment., Fleming ... on the market ranged from 40% all the way ...
... Diana Kirschner Explains the Psychology Behind It, NEW ... an estimated,$55.7 million for its opening weekend, beating out ... other romantic comedy has ever,opened with such a lucrative ... occurring," says Dr. Diana Kirschner, psychologist and,recurring relationship expert ...
... Expects FDA to Request Additional Safety Study Prior to ... Inc.,(Nasdaq: IDEV ) today announced that based on ... (FDA) regarding the NDA filing for,NEBIDO(R), the Company expects ... safety data prior to approving NEBIDO. The Company,currently believes ...
... risk of developing rheumatoid arthritis by up to 50%, ... of the Rheumatic Diseases. , The Scandinavian researchers base ... in two separate studies, which assessed environmental and genetic ... the participants (1650) had the disease and had been ...
... FALLS CHURCH, Va., June 4 CSC (NYSE: ... Dell Inc. (Nasdaq: DELL ) to design and,deploy ... and,complexity out of their information technology (IT) environment and ... help clients,simplify processes associated with IT and enhance innovation ...
... to Ensure Equitable Protections,for All Americans and Their ... America,s,Health (TFAH) issued the following statement on the ... Services(HHS) Draft Guidances to Assist in,Preparation for an ... government must do all it can to ensure ...
Cached Medicine News:Health News:The Vitamin B12 Craze - Super Nutrient or Super Hype? 2Health News:Why is the Sex & the City Movie a Mega-Blockbuster? 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 3Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 4Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 5Health News:Regular tipple may curb risk of rheumatoid arthritis 2Health News:CSC to Simplify IT From Desktop to Data Center 2Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2
... The Optimal temporary implant for use with ... The pupil dilator type 5S is a ... of the pupil during phacoemulsification. It is ... use. Indication: Expansion of the pupil during ...
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
For use with Crawford Intubation Systems....
... prolene as thread-guide reducing time and trauma ... Probe is inserted into the nasolacrimal duct ... through it. The probe is then withdrawn ... silicone tubing in place. Canalicular Laceration or ...
Medicine Products: